Profil
Patrick M.
Shea is currently the Chief Executive Officer & Director at Intrance Medical Systems, Inc. He previously worked as a Director at OSI Pharmaceuticals, Inc.
Postes actifs de Patrick M. Shea
| Sociétés | Poste | Début |
|---|---|---|
Intrance Medical Systems, Inc.
 Intrance Medical Systems, Inc. Pharmaceuticals: MajorHealth Technology Intrance Medical Systems, Inc. is a company focused on developing and commercializing clinical products for the treatment of advanced Parkinson's disease. The company is based in Albany, NY. Recently, the company appointed Ashley Prange as Vice President of Business Development to strengthen its focus on strategic partnerships, including out-licensing activities and commercial collaborations. Parkinson's disease is the second most common neurodegenerative disorder, affecting nearly one million people in the United States. The company was founded in 2018 by Ulf Rosén and Roger Bolsöy. The CEO is Patrick M. Shea. | Directeur Général | 13/05/2021 |
Anciens postes connus de Patrick M. Shea
| Sociétés | Poste | Fin |
|---|---|---|
| OSI PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
Intrance Medical Systems, Inc.
Intrance Medical Systems, Inc. Pharmaceuticals: MajorHealth Technology Intrance Medical Systems, Inc. is a company focused on developing and commercializing clinical products for the treatment of advanced Parkinson's disease. The company is based in Albany, NY. Recently, the company appointed Ashley Prange as Vice President of Business Development to strengthen its focus on strategic partnerships, including out-licensing activities and commercial collaborations. Parkinson's disease is the second most common neurodegenerative disorder, affecting nearly one million people in the United States. The company was founded in 2018 by Ulf Rosén and Roger Bolsöy. The CEO is Patrick M. Shea. | Health Technology |